Thursday, September 12, 2019 10:23:43 PM
Restricted from back in 2013
"On July 19, 2013, Discovery Gold Corporation, a Nevada corporation (the “Company”) and Steven Ross entered into a Loan Conversion Agreement pursuant to which the parties agreed to convert loans from Steven Ross in an aggregate amount of $30,000 plus the accrued interest of $1,134.25 into 7,783,562 restricted shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and a eighteen-month warrant to purchase 3,750,000 shares of Common Stock at an exercise price of $0.02 per share.
On July 19, 2013, the Company entered into a subscription agreement with Steven Ross whereby it sold 12,500,000 units (the “Units”) of its securities for $50,000. Each of the Units was sold at a purchase price of $0.004 per Unit. Each Unit consists of (i) one share of Common Stock and (ii) one warrant to purchase 0.5 share of Common Stock at a per share exercise price of $0.02. "
https://www.otcmarkets.com/filing/html?id=9458104&guid=4VlfUKfz-6uMgyh
"On July 19, 2013, Discovery Gold Corporation, a Nevada corporation (the “Company”) and Steven Ross entered into a Loan Conversion Agreement pursuant to which the parties agreed to convert loans from Steven Ross in an aggregate amount of $30,000 plus the accrued interest of $1,134.25 into 7,783,562 restricted shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and a eighteen-month warrant to purchase 3,750,000 shares of Common Stock at an exercise price of $0.02 per share.
On July 19, 2013, the Company entered into a subscription agreement with Steven Ross whereby it sold 12,500,000 units (the “Units”) of its securities for $50,000. Each of the Units was sold at a purchase price of $0.004 per Unit. Each Unit consists of (i) one share of Common Stock and (ii) one warrant to purchase 0.5 share of Common Stock at a per share exercise price of $0.02. "
https://www.otcmarkets.com/filing/html?id=9458104&guid=4VlfUKfz-6uMgyh
Recent MAJI News
- Form 253G2 - • Edgar (US Regulatory) • 05/26/2026 06:00:08 PM
- NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist • GlobeNewswire Inc. • 05/11/2026 03:53:17 PM
- NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test • GlobeNewswire Inc. • 04/07/2026 02:30:00 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/30/2026 04:15:02 AM
- Form 253G1 - • Edgar (US Regulatory) • 03/27/2026 07:12:08 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/26/2026 08:25:15 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/20/2026 08:23:33 PM
- Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value • GlobeNewswire Inc. • 03/16/2026 02:15:00 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/11/2026 07:11:39 PM
- Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions • GlobeNewswire Inc. • 03/05/2026 06:00:20 PM
- Form 1-A POS - • Edgar (US Regulatory) • 02/19/2026 09:39:04 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/11/2026 08:06:08 PM
- Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition • GlobeNewswire Inc. • 02/10/2026 03:30:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 01/15/2026 06:47:01 PM
- Form 253G1 - • Edgar (US Regulatory) • 01/14/2026 09:54:45 PM
- Form 1-A POS - • Edgar (US Regulatory) • 12/31/2025 12:32:47 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/29/2025 08:29:49 PM
- Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization • ACCESS Newswire • 12/11/2025 05:15:00 PM
- Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement • ACCESS Newswire • 12/05/2025 04:00:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/04/2025 09:35:28 PM
- Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms • ACCESS Newswire • 12/02/2025 06:45:00 PM
- Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value • ACCESS Newswire • 11/17/2025 08:40:00 PM
- Exousia Pro Announces Breakthrough In Exosome-Based Delivery • ACCESS Newswire • 11/04/2025 03:40:00 PM
- Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA • ACCESS Newswire • 10/28/2025 02:20:00 PM

